Breaking Down Blue Sail Medical Co.,Ltd. Financial Health: Key Insights for Investors

Blue Sail Medical Co., Ltd. (002382.SZ) presents a mixed financial picture that demands close investor attention: operating revenue for the first three quarters of 2025 totaled 4.182 billion yuan (down 10.15% YoY) while TTM revenue ended September 30, 2025 at 5.78 billion yuan (down 3.61% YoY) after a 2024 full-year revenue of 6.25 billion yuan (+26.91% YoY); profitability shows a net loss of 286 million yuan attributable to shareholders in the first nine months of 2025 with a TTM net profit margin of -8.85% and gross margin at 13.20%, and quarterly swings from a Q1 net profit of 77.02 million yuan (+177.86% YoY) to Q2 and Q3 losses of 211.80 million yuan and 151.18 million yuan respectively; the balance sheet reveals total assets of 16.84 billion yuan, total liabilities of 6.94 billion, total equity of 9.90 billion, total debt of 1.09 billion and a debt-to-equity ratio of 52.44% as of June 30, 2025, while liquidity shows cash and cash equivalents of 2.83 billion yuan (up 48.47% YoY), a current ratio of 0.87, quick ratio of 0.63, operating cash flow (TTM) of 580 million yuan and free cash flow (TTM) of 192.53 million yuan; valuation metrics include a market capitalization of 5.64 billion yuan, P/S of 0.97, EV/EBITDA of 82.85 and P/B of 0.69 with TTM EPS of -0.50, and risk/recovery levers range from an interest coverage ratio of -1.47 to growth drivers such as a cardiovascular division exceeding 1.1 billion yuan in sales (+~12% YoY), health protection revenue up >33% nearing breakeven, Asia‑Pacific sales growth of ~23%, a 1 billion yuan strategic investment into a subsidiary, and R&D spending around 200 million yuan in the cardiovascular division-read on for a detailed breakdown and actionable insights for investors.

Blue Sail Medical Co.,Ltd. (002382.SZ) Revenue Analysis

Blue Sail Medical's topline in 2025 showed mixed momentum across quarters with an overall contraction year-on-year through the first three quarters. Key figures:

• Operating revenue, first three quarters 2025: 4.182 billion yuan (YoY -10.15%).
• Q1 2025: 1.478 billion yuan (YoY +1.59%).
• Q2 2025: 1.302 billion yuan (YoY -16.00%).
• Q3 2025: 1.401 billion yuan (YoY +7.57%).
• TTM revenue ending 30 Sep 2025: 5.78 billion yuan (YoY -3.61%).
• Full-year revenue 2024: 6.25 billion yuan (YoY +26.91% vs. 2023).

Revenue dynamics and implications for investors:

• Volatility across quarters: Q2 2025 marked a pronounced drop (-16.0%) while Q3 posted a rebound (+7.57%), indicating intra-year cyclicality or one-off impacts.
• TTM decline (-3.61%) despite 2024's robust growth (+26.91%) suggests 2025 faces headwinds relative to last year's strong base.
• Quarterly sequencing: Q1 resilience, Q2 weakness, Q3 recovery - monitor Q4 and FY-2025 guidance to assess whether recovery sustains.
• Investors should cross-reference revenue trends with margin, order backlog, and product mix disclosures for a fuller picture; see company strategic context at Mission Statement, Vision, & Core Values (2026) of Blue Sail Medical Co.,Ltd.

Blue Sail Medical Co.,Ltd. (002382.SZ) Profitability Metrics

Blue Sail Medical's recent profitability profile shows sharp intra-year volatility with a cumulative net loss for the first three quarters of 2025 and weak trailing margins. Key headline figures:

• Net loss attributable to shareholders for first three quarters of 2025: ¥286.00 million.
• Q1 2025 net profit attributable to shareholders: ¥77.0223 million (YoY +177.86%).
• Q2 2025 net loss attributable to shareholders: ¥211.80 million (YoY increase of 245.53%).
• Q3 2025 net loss attributable to shareholders: ¥151.18 million (YoY decrease of 28.58%).
• TTM net profit margin: -8.85%.
• TTM gross profit margin: 13.20%.

The quarter-by-quarter swing demonstrates a profitable Q1 followed by two loss-making quarters that drove the YTD cumulative loss. Below is a compact tabular view of these profitability datapoints:

• Gross margin at 13.20% TTM indicates limited markup headroom; combined with a negative TTM net margin (-8.85%), operating leverage and cost control are pressing issues.
• Large Q2 loss (¥211.80m) is the primary driver of the YTD deficit despite Q1's strong recovery; Q3 reduced the YoY loss by 28.58% but remained negative.
• Investors should track quarterly operating expenses, one-off items and revenue seasonality to understand whether margins can normalize.

Contextual background and corporate history can be found here: Blue Sail Medical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Blue Sail Medical Co.,Ltd. (002382.SZ) - Debt vs. Equity Structure

• Total assets: 16.84 billion yuan
• Total liabilities: 6.94 billion yuan
• Total equity: 9.90 billion yuan
• Total debt: 1.09 billion yuan
• Debt-to-equity ratio: 52.44%
• Current ratio: 0.87
• Quick ratio: 0.63
• Interest coverage ratio: -1.47

• Leverage: At a 52.44% debt-to-equity ratio, leverage is moderate - equity (9.90 billion) substantially exceeds recorded debt (1.09 billion), leaving room for debt-funded growth but limited buffer if operating performance deteriorates.
• Liquidity stress: Current ratio 0.87 and quick ratio 0.63 indicate current liabilities exceed current assets; working-capital management or short-term financing may be needed to avoid cash‑flow strain.
• Coverage concern: Interest coverage of -1.47 signals operating losses relative to interest expense, implying earnings are insufficient to cover interest - a red flag for creditworthiness until operating profitability improves.
• Balance-sheet resilience: Large total assets (16.84 billion) and equity (9.90 billion) provide collateral and solvency headroom despite near-term liquidity and earnings issues.

Blue Sail Medical Co.,Ltd. (002382.SZ) Liquidity and Solvency

• Cash and cash equivalents (as of 2025-06-30): ¥2.83 billion (+48.47% YoY)
• Operating cash flow (TTM): ¥580 million
• Net income (TTM): -¥511.75 million
• Net change in cash (TTM): -¥375.04 million
• Free cash flow (TTM): ¥192.53 million
• Cash to current liabilities ratio: 85.43%

• High cash buffer (¥2.83B) improves short-term solvency and provides runway for investment or funding gaps.
• Operating cash flow (¥580M) and positive free cash flow (¥192.53M) indicate underlying cash-generating capacity despite accounting losses.
• Negative net income (-¥511.75M) warrants scrutiny of one-time or non-cash charges; reconciliation between EBITDA/OCF and net loss is important.
• Net cash declined by ¥375.04M over the TTM-monitor whether cash burn is temporary (seasonal capex, M&A) or structural.
• Cash-to-current-liabilities at 85.43% implies relatively high coverage but not full coverage; short-term liquidity risk remains if receivables or inventories cannot be converted quickly.

Blue Sail Medical Co.,Ltd. (002382.SZ) - Valuation Analysis

• Market capitalisation: 5.64 billion CNY
• Price-to-Sales (P/S): 0.97 - roughly 1x revenue, signaling market pricing close to one year of sales
• Price-to-Book (P/B): 0.69 - below 1, implying the market values the company below its book equity

• Revenue/Equity multiples (P/S ~0.97, P/B ~0.69) indicate a valuation that can appear attractive on surface fundamentals.
• Profitability and cash-flow metrics (EPS -0.50, EV/EBITDA 82.85, EV/FCF -49.86) signal weak operating performance - high capital market valuation ratios driven by negative denominators.
• When EV/EBITDA and EV/FCF are distorted by negative or near-zero EBITDA/FCF, reliance on P/S and P/B requires cross-checking with operational trends, margins, and cash conversion.

Blue Sail Medical Co.,Ltd. (002382.SZ) Risk Factors

• Net loss and profitability pressure: net loss attributable to shareholders of ¥286 million for the first three quarters of 2025; TTM net profit margin of -8.85% signals ongoing unprofitability.
• Leverage and solvency risk: debt-to-equity ratio of 52.44% indicates a relatively high level of debt financing versus equity, increasing financial leverage risk.
• Interest burden: interest coverage ratio of -1.47 suggests operating earnings are insufficient to cover interest expenses, raising default and refinancing concerns.
• Operational cash flow vs. profitability divergence: positive operating cash flow of ¥580 million mitigates some short-term liquidity worries despite accounting losses, but persistent losses could erode cash buffers.
• Capital allocation and growth: positive free cash flow of ¥192.53 million supports reinvestment or deleveraging, but the magnitude may be insufficient if losses continue or capital needs rise.
• Market and execution risks: continued negative margins and weakening coverage can limit strategic flexibility (M&A, R&D, commercialization) and raise investor scrutiny.
• Refinancing and interest-rate risk: with meaningful debt and negative interest coverage, rising rates or tighter credit conditions could materially increase financing costs or restrict access to capital.

• Key scenarios investors should model:
  • Base: sustained positive operating cash flow with gradual margin recovery enabling deleveraging.
  • Downside: continued negative margins leading to cash burn and need for equity/debt raising at dilutive or costly terms.
  • Stress: rising rates push interest expense higher while revenue growth stalls, exacerbating coverage and solvency pressures.
• Monitoring checklist for investors: quarterly profitability trends, cash burn vs. operating cash flow, debt maturities and cost, management guidance on margin improvement and capital allocation.

Blue Sail Medical Co.,Ltd. (002382.SZ) - Growth Opportunities

• Cardiovascular division momentum: sales revenue exceeded 1.1 billion yuan, a year‑on‑year rise of about 12%.
• Health protection division acceleration: revenue rose by over 33% year‑on‑year and is approaching breakeven.
• Asia‑Pacific expansion: regional sales grew approximately 23%, led by stronger shipments of coronary and valve products.

• Strategic external financing: a 1 billion yuan strategic investment secured for a subsidiary, providing capital for capacity expansion and market development.
• R&D commitment: roughly 200 million yuan invested in cardiovascular R&D to strengthen product competitiveness and pipeline depth.
• Margin improvement via efficiency: cost reduction and efficiency measures lifted the health protection division's gross margin by about 8 percentage points.

• Scale production in cardiovascular implants and valves to convert the ~12% revenue growth into higher margin volume.
• Leverage the 1 billion yuan strategic funding to accelerate market entry and sales channels in APAC and adjacent regions.
• Convert the health protection division's revenue momentum and margin gains into sustained profitability through pricing, mix and continued efficiency programs.
• Deploy the ~200 million yuan cardiovascular R&D to advance differentiated products that command premium pricing and defend market share.